Alzheimer's contract wins
IXICO plc
(“IXICO”, the “Company” or the “Group”)
IXICO ANNOUNCES TWO CONTRACTS IN ALZHEIMER’S DISEASE
WORTH £1.5 MILLION
Contracts reflect IXICO’s ability to unlock the value of its IXI™ technology platform across an increasing array of customer types
News follows a FY26 trading update which exceeded revenue expectations
22 October 2026, IXICO plc (AIM: IXI) – London, UK. IXICO, a global TechBio leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, today announces two contracts with a combined value of approximately £1.5 million.
The contract news follows a positive trading update made by IXICO on 20 October, which reported 28% revenue growth for FY26, and further strengthens the Company’s position in Alzheimer’s disease (AD) diagnostics and clinical development.
The first contract is with a biotechnology company to manage and analyse neuroimaging for a Phase 2b clinical trial in AD. Revenue from this contract is expected to be recognised across approximately three years.
The second win is a contract extension with an existing large international life sciences and diagnostics client. The project will continue to utilise IXICO’s proprietary IXI™ neuroimaging technology platform to support the validation and regulatory approval for a blood-based biomarker (“BBBM”) being developed to diagnose AD. Revenue from this contract is expected to be recognised within one year and expands the £16 million order book reported at the trading update.
Bram Goorden, Chief Executive Officer of IXICO, commented: “Securing these two contracts again demonstrates the breadth of IXICO’s capabilities in Alzheimer’s disease, supporting both the development of new therapeutics and the emerging generation of diagnostics. These contracts strengthen our order book and provide commercial colour to the positive trading update we made two days ago. Most importantly this is rewarding for the full team and a testament to our recognised capabilities in Alzheimer’s.”
Ends
For further information please contact:
IXICO plc
+44 (0) 20 3763 7499
Grant Nash, Chief Financial Officer
James Chandler, Chief Business Officer
Cavendish Capital Markets Limited
(Nominated Adviser and Sole Broker)
+44 (0) 20 7220 0500
Giles Balleny, Isaac Hooper (Corporate Finance)
Nigel Birks (Healthcare Specialist Sales)
Harriet Ward (Corporate Broking)
Michael F Johnson (Sales)
About IXICO www.IXICO.com
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech’s, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.
The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Image data is interrogated by the Platform and IXICO’s expert scientists translating complex data into clinically meaningful insights while minimizing data variability and increasing reproducibility.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDCNTQBLFLQBLZFBB
